• Nineteen of 224 renal allograft recipients who were prospectively randomized to receive either cyclosporine (n = 117) or azathioprine sodium—antilymphocyte globulin (n = 107) for immunosuppression suffered from one period of pneumonia (14 azathioprine and five cyclosporine recipients); two recipients of azathioprine had two episodes. Four patients in the azathioprine group and one in the cyclosporine group died, for mortalities of 3.7% and 0.85%, respectively. The percentage of pneumonia-free patients at one year was 96.3% in the cyclosporine group while it was 90.8% in the azathioprine group. Nondiabetics, women, and recipients of grafts from living related donors were at a statistically lower risk of developing pneumonia when treated with cyclosporine. Viral (cytomegalovirus), fungal (Candida, Aspergillus), and multibacterial causes of pneumonia each occurred with a similar incidence.
(Arch Surg 1986;121:1056-1060)
Hesse UJ, Fryd DS, Chatterjee SN, Simmons RL, Sutherland DER, Najarian JS. Pulmonary Infections: The Minnesota Randomized Prospective Trial of Cyclosporine vs Azathioprine-Antilymphocyte Globulin for Immunosuppression in Renal Allograft Recipients. Arch Surg. 1986;121(9):1056–1060. doi:10.1001/archsurg.1986.01400090086015
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: